Michael Threlkeld, MD
Infectious Disease · Memphis, TNNPI 1356318661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 28.7% of the total. Reporting peaked in 2019 at $1,374 and has fallen 52.6% since, to $651 in 2025.
Across 244 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Merck$572
- Astellas Pharma US Inc$550
- Insmed, Inc.$412
- Gilead$395
- Viiv Healthcare Company$319
- plus $975 from 15 others
What the payments were for
- Food & beverage$4,506100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $1,298 |
| Merck | 36 | $572 |
| Astellas Pharma US Inc | 24 | $550 |
| Insmed, Inc. | 23 | $412 |
| Gilead | 24 | $395 |
| Viiv Healthcare Company | 19 | $319 |
| Pfizer | 16 | $277 |
| Tetraphase Pharmaceuticals, Inc. | 9 | $152 |
| Cumberland Pharmaceuticals, Inc. | 4 | $130 |
| Melinta Therapeutics, LLC | 7 | $95 |
| Theratechnologies Inc. | 4 | $59 |
| EMD Serono, Inc. | 3 | $54 |
| Vyera Pharmaceuticals, LLC | 3 | $52 |
| Johnson & Johnson | 3 | $38 |
| Mayne Pharma Commercial LLC | 2 | $29 |
| Smith+Nephew | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| KCI USA, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Medela LLC | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
How this compares
$4,522 in reported general payments places this provider in the 80th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MicafunginMicafungin Sodium | 15 | $7,373 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 26 | $6,260 |
| ErtapenemErtapenem Sodium | 13 | $5,268 |
| Vancomycin Hcl | 34 | $3,553 |
| Ampicillin Sodium | 17 | $2,823 |
| Daptomycin | 13 | $2,354 |
| Cefepime Hcl | 15 | $1,610 |
| CeftriaxoneCeftriaxone Sodium | 33 | $747 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Memphis
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Stephen ThrelkeldMemphis$27K
- Imad OmerMemphis$22K
- Margarita LamotheMemphis$12K
- Daniel MurrellMemphis$12K
- James DaleMemphis$8K
- Kristie NowakMemphis$2K
- Shirin MazumderMemphis$2K
- Chiemeziem NwanyanwuMemphis$899
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.